Skip to main content

Table 4 Summary of base case results

From: The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation

Treatment

Total costs (£)

Total QALYs

ICER vs. BSC (£/QALY)

ICER vs. next best option (£/QALY)

BSC

3,084

2.98

-

-

Azathioprine & prednisolone

4,313

2.66

Dominated

Dominated

NAC triple therapy

5,021

3.03

41,811

Extended Dominance

Inhaled NAC

5,029

3.37

5,037

5,037

Sildenafil

12,008

3.11

68,116

Dominated

Pirfenidone

70,118

3.34

190,146

Dominated

Nintedanib

139,613

4.01

132,658

209,246

  1. NB: Nintedanib uses an assumed cost.